Hormone Replacement Trial Against ALzheimers' Disease

Recruiting now · Not applicable

Conditions studied: Postmenopausal Symptoms, Alzheimer Disease

In brief

The influence of postmenopausal hormone treatment on dementia is not clear. Dysfunctions in the metabolism of amyloid in the disease of Alzheimer result in an elevated presence of degradation products in cerebrospinal fluid. The degradation products in blood will be analysed during the trial, to get better insight in menopause and the start of hormonal therapy. Postmenopausal women with and without history of breast cancer will be recruited for the trial.

Key facts

Study ID

NCT04312399

Run by

University Hospital, Ghent

People needed

600

Starts

2018-04-17

Expected to finish

2028-12-31

Last updated by the study team

2025-01-27

Who can join

Age: 40 and older, up to 65. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• postmenopausal women
• 40 - 65 years

You may not qualify if…

• Longer than 10 years in menopause
• thyroid dysfunction
• hypertension
• medical history of psychiatric comorbidity
• Alcohol and/or drug abuse
• medical history of neurologic symptoms with cognitive symptoms

Where it is running

• Ghent university hospital — Ghent, Belgium (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.